However, directly related to this success have been a number of controversies for Gilead. The people being treated for HIV are often among the most vulnerable, and the virus disproportionately ...

Twinning this cutting-edge cell therapy science with the expertise of Gilead in HIV and hepatitis C therapeutics, plus its massive marketing success, should ensure major success for the company.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

These factors collectively justify the optimistic outlook and Buy rating for Gilead Sciences. According to TipRanks, Breen is an analyst with an average return of -5.8% and a 33.33% success rate.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately ...

Gilead's cell therapy franchise has already faced pressures, and this trend is expected to continue. The success of key products like Trodelvy and anito-cel is crucial for Gilead's oncology ...

Before joining Gilead, Berger was previously the chief medical officer and global head of development at Sanofi, focusing on development science, strategy ... and Merdad played a fundamental role in ...

Gilead's cell therapy franchise has already faced pressures, and this trend is expected to continue. The success of key products like Trodelvy and anito-cel is crucial for Gilead's oncology ambitions, ...